by Truveta staff | Jan 26, 2024 | Research
Truveta Research explored the rates of pediatric RSV immunizations and pediatric RSV-associated hospitalizations for children under the age of two. Of the 1,872,292 children under age two who were eligible to receive an RSV immunization, 3.7% of the eligible...
by Truveta staff | Jan 23, 2024 | Research
Overall, the rate of hospitalizations associated with respiratory viruses continues to increase (92.8% increase from November 2023 to the end of December 2023). The largest increases in hospitalizations over the past month were associated with influenza (251.7%...
by Truveta staff | Jan 23, 2024 | Research
Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) have remained stable in the last 3 months, with rates in December 2023 about the same as rates in November 2023 and October 2023. For the anti-diabetic medications (ADMs), the number of...
by Truveta Research | Jan 11, 2024 | Research, Research Insights
There is a complex relationship between cannabis use and mental health. We studied recent time trends of the rate of cannabis-induced disorder emergency department visits and cannabis-involved emergency department visits (both defined below). Between 2019 and 2020, we...
by Truveta staff | Dec 15, 2023 | Research
As 2023 draws to a close and we reflect on a busy and exciting year for Truveta, something that stands out is the breadth and depth of research Truveta Research has been able to produce using Truveta Data and Truveta Studio. From studying new Alzheimer’s disease...
by Truveta Research | Nov 27, 2023 | Research, Research Insights
In the first comparative effectiveness study of tirzepatide (Mounjaro) and semaglutide (Ozempic) for weight loss using real-world data, Truveta Research found that patients with overweight or obesity taking tirzepatide were three times more likely to achieve 15%...
